Copyright © 2008 RhinoCyte, Inc.
1. Adult Human Olfactory Stem Cells
Patent filed March 2001
Culture and use of human adult rhino-epithelial derived stem cells for
treating neurological disorders NEW!!! Australian Patent Number 2003223162 Approved May 12, 2009 (click link)
2. Transcription Factors For Differentiation of
Adult Human Olfactory Progenitor Cells
Patent filed August 31, 2006
Lineage Restriction of stem cells prior to transplantation 3. Orphan Drug Designation Granted Feb. 1, 2008 (click link) Pursuant to section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb),
your request for orphan-drug designation of autologous olfactory neural progenitors
(trade name: Rhinocytes) is granted for treatment of spinal cord injury patients with
ASIA Impairment grades of A, B, or C. 4. Olfactory Epithelial-Derived Stem Cells and Methods of Use Therefor Patent filed October 31, 2008 Use of stem cells for Parkinson's disease
5. Orphan Drug Designation for Treatment of ALS Granted Dec. 31, 2008
RhinoCyte, Inc. just received notification that on December 31, 2008 a second Orphan Drug Designation Application was approved. The following is a section of the FDA’s approval letter:
“Reference is made to your request for orphan-drug designation submitted on behalf of RhinoCyte, Inc. on April 2, 2008, of autologous olfactory neural progenitors (trade name: RhinoCytes™) for “treatment of amyotrophic lateral sclerosis (ALS).” Please also refer to our letters of April 8 and July 17, 2008, and to your submission dated September 29, 2008.
Pursuant to section 526 of the Federal Food, Drug, and Cosmetics Act (21 U.S.C. 360bb), your request for orphan-drug designation of autologous olfactory neural progenitors (trade name: RhinoCytes™) is granted for treatment of amyotrophic lateral sclerosis (ALS).”
6. Exclusive worldwide rights licensed from the University of Louisville